markdownabstract__Introduction__ Cognitive testing in Alzheimer's disease (AD) is essential for establishing diagnosis, monitoring progression, and evaluating treatments. Assessments should ideally be brief, reliable, valid, and reflect clinically meaningful changes. There is a lack of instruments that meet all these criteria. In the Capturing Changes in Cognition (Catch-Cog) study, we seek to correct these deficiencies through the development and validation of a composite measure combining cognition and function: the cognitive-functional composite (CFC). We expect that the CFC is able to detect clinically relevant changes over time in early dementia stages of AD. __Methods/Design__ We will include patients (n = 350) with mild cognitive ...
Copyright © INS. Published by Cambridge University Press, 2020.Objective: Alzheimer's disease (AD) s...
INTRODUCTION: Recent Food and Drug Administration guidance endorses cognitive assessment as a possib...
Cognitively-normal people with evidence of β-amyloid (Aβ) pathology and subtle cognitive dysfunction...
Introduction Cognitive testing in Alzheimer's disease (AD) is essential for establishing diagnosis, ...
Introduction Cognitive testing in Alzheimer's disease (AD) is essential for establishing diagnosis, ...
textabstractIntroduction: To improve the detection of changes in Alzheimer's disease (AD), we design...
Background: The cognitive-functional composite (CFC) was designed to improve the measurement of clin...
BackgroundThe cognitive-functional composite (CFC) was designed to improve the measurement of clinic...
Introduction: In an attempt to capture clinically meaningful cognitive decline in early dementia, we...
Background: There is a growing consensus that disease-modifying therapies must be given at the prodr...
BackgroundThe cognitive-functional composite (CFC) was designed to improve the measurement of clinic...
International audienceOBJECTIVE: To investigate the sensitivity of a large set of neuropsychological...
INTRODUCTION: We established a method for diagnostic harmonization across multiple studies of precli...
Background: We sought to identify optimal approaches by calibrating longitudinal cognitive performan...
Copyright © INS. Published by Cambridge University Press, 2020.Objective: Alzheimer's disease (AD) s...
INTRODUCTION: Recent Food and Drug Administration guidance endorses cognitive assessment as a possib...
Cognitively-normal people with evidence of β-amyloid (Aβ) pathology and subtle cognitive dysfunction...
Introduction Cognitive testing in Alzheimer's disease (AD) is essential for establishing diagnosis, ...
Introduction Cognitive testing in Alzheimer's disease (AD) is essential for establishing diagnosis, ...
textabstractIntroduction: To improve the detection of changes in Alzheimer's disease (AD), we design...
Background: The cognitive-functional composite (CFC) was designed to improve the measurement of clin...
BackgroundThe cognitive-functional composite (CFC) was designed to improve the measurement of clinic...
Introduction: In an attempt to capture clinically meaningful cognitive decline in early dementia, we...
Background: There is a growing consensus that disease-modifying therapies must be given at the prodr...
BackgroundThe cognitive-functional composite (CFC) was designed to improve the measurement of clinic...
International audienceOBJECTIVE: To investigate the sensitivity of a large set of neuropsychological...
INTRODUCTION: We established a method for diagnostic harmonization across multiple studies of precli...
Background: We sought to identify optimal approaches by calibrating longitudinal cognitive performan...
Copyright © INS. Published by Cambridge University Press, 2020.Objective: Alzheimer's disease (AD) s...
INTRODUCTION: Recent Food and Drug Administration guidance endorses cognitive assessment as a possib...
Cognitively-normal people with evidence of β-amyloid (Aβ) pathology and subtle cognitive dysfunction...